Synthetic Biology Company Evonetix Appoints Paul Beastall As Chair of Board of Directors

Paul Beastall

On April 25, 2022, EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, announced the appointment of Paul Beastall (photo) as Chair of the Board of Directors. Paul was previously a Non-Executive Director at Evonetix, having joined the Board in 2020. His new appointment to Chair will see him take a more involved role in guiding product development strategy. This announcement follows the company’s recent patent grant for technology enabling thermally-controlled DNA synthesis. Beastall has over 20 years’ experience in product development, global industrial and consumer markets, and strategic consultancy, previously holding senior positions at start-ups, large corporations, government, and consultancy businesses. His most recent role was Strategy Director at Cambridge Consultants, where he worked with the executive team to develop business strategy and partnerships, before joining Evonetix as Non-Executive Chair. Beastall holds a master’s degree in electronic systems engineering from the University of York and is a Fellow of the Institution of Engineering and Technology.

Login Or Register To Read Full Story